Clinical Trial Update: Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating tolerability, safety, and antibody response to the G17DT vaccine in patients with gastric cancer (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• G17DT

Snippet

Sponsor: Cancer Advances Inc. | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED